EW — Edwards Lifesciences Corporation stock price and chart

Edwards Lifesciences CorporationStock · HealthcareS&P 500 Equal Weight 0.2% · S&P 500 0.08% · Russell 1000 0.07% · US Stock Market 0.07% · Russell 3000 0.07% · MSCI World 0.06% · MSCI ACWI 0.05%

$84.37-2.77%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

VolumeS

20162019202120242026

30.040.050.060.070.080.090.0100.0110.0120.0050.0M100.0M$84.37

2026-09-11

Price$84.37

MA20$86.21

MA50$83.07

Vol16.9M

What would $1,000 invested in EW be worth today? →

EW returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $84.37
Change YTD: -1.03%
Next earnings: Oct 29, 2026
Market cap: 48.6B2016-09 25.8B2026-09 48.7B+88.7% over the window
Enterprise value: 45.2B
Shares outstanding: 576.4M2016-06 638.6M2026-06 576.4M-9.7% over the window
52W low: $72.30
52W high: $96.29
From 52W high: -12.38%
From 52W low: +16.69%
52W range: 50%
Beta: 0.84

Volume

Rel volume: 1.27×
30D volume: 3M
30D $ vol: 268.1M

Fundamentals

Sales (ttm): 6.5B2016-06 2.7B2026-06 6.5B+137.4% over the window
Sales/share: $11.302016-06 $4.302026-06 $11.30+163.0% over the window
EPS (ttm): $1.732016-06 $0.812026-06 $1.73+114.3% over the window
FCF (ttm): 1.4B2016-06 475.4M2026-06 1.4B+201.6% over the window
FCF/share: $2.492016-06 $0.742026-06 $2.49+234.1% over the window
Book value/share: $18.422016-06 $3.872026-06 $18.42+376.1% over the window
Net margin: 15.43%2016-06 19.3%2026-06 15.4%-19.9% over the window
ROE: 9.46%2016-06 21.4%2026-06 9.5%-55.7% over the window
ROA: 7.25%2016-06 13.0%2026-06 7.2%-44.4% over the window
Debt / equity: 0.06×2016-06 0.242026-06 0.06-76.9% over the window
Current ratio: 4.522016-12 4.212026-06 4.52+7.5% over the window

Growth (CAGR, ttm) · 10Y

Sales: +14.56%2025-06-30 → 2026-06-305.7B → 6.5B (+14.6% total)+15.29%2023-06-30 → 2026-06-304.2B → 6.5B (+53.3% total)+5.75%2021-06-30 → 2026-06-304.9B → 6.5B (+32.2% total)+9.03%2016-06-30 → 2026-06-302.7B → 6.5B (+137.4% total)
Net income: -75.80%2025-06-30 → 2026-06-304.1B → 1B (-75.8% total)-10.24%2023-06-30 → 2026-06-301.4B → 1B (-27.7% total)-7.23%2021-06-30 → 2026-06-301.5B → 1B (-31.3% total)+6.64%2016-06-30 → 2026-06-30528.4M → 1B (+90.2% total)
FCF: +144.00%2025-06-30 → 2026-06-30587.9M → 1.4B (+143.9% total)+26.85%2023-06-30 → 2026-06-30702.2M → 1.4B (+104.2% total)+6.41%2021-06-30 → 2026-06-301.1B → 1.4B (+36.4% total)+11.67%2016-06-30 → 2026-06-30475.4M → 1.4B (+201.6% total)
Shares: -1.82%2025-06-30 → 2026-06-30587.1M → 576.4M (-1.8% total)-1.76%2023-06-30 → 2026-06-30607.9M → 576.4M (-5.2% total)-1.55%2021-06-30 → 2026-06-30623.3M → 576.4M (-7.5% total)-1.02%2016-06-30 → 2026-06-30638.6M → 576.4M (-9.7% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -75.15%2025-06-30 → 2026-06-30$6.95 → $1.73 (-75.1% total)-8.52%2023-06-30 → 2026-06-30$2.26 → $1.73 (-23.4% total)-5.80%2021-06-30 → 2026-06-30$2.33 → $1.73 (-25.8% total)+7.92%2016-06-30 → 2026-06-30$0.81 → $1.73 (+114.3% total)
Sales/share: +16.69%2025-06-30 → 2026-06-30$9.68 → $11.30 (+16.7% total)+17.36%2023-06-30 → 2026-06-30$6.99 → $11.30 (+61.6% total)+7.41%2021-06-30 → 2026-06-30$7.90 → $11.30 (+43.0% total)+10.16%2016-06-30 → 2026-06-30$4.30 → $11.30 (+163.0% total)
FCF/share: +148.53%2025-06-30 → 2026-06-30$1.00 → $2.49 (+148.4% total)+29.12%2023-06-30 → 2026-06-30$1.16 → $2.49 (+115.3% total)+8.09%2021-06-30 → 2026-06-30$1.69 → $2.49 (+47.6% total)+12.82%2016-06-30 → 2026-06-30$0.74 → $2.49 (+234.1% total)
Book value/share: +2.56%2025-06-30 → 2026-06-30$17.96 → $18.42 (+2.6% total)+20.65%2023-06-30 → 2026-06-30$10.49 → $18.42 (+75.6% total)+17.47%2021-06-30 → 2026-06-30$8.24 → $18.42 (+123.7% total)+16.89%2016-06-30 → 2026-06-30$3.87 → $18.42 (+376.1% total)
Price: +8.16%2025-09-11 → 2026-09-11$78.01 → $84.37 (+8.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+4.06%2023-09-11 → 2026-09-11$74.87 → $84.37 (+12.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-6.94%2021-09-10 → 2026-09-11$120.89 → $84.37 (-30.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+8.24%2016-09-09 → 2026-09-11$38.20 → $84.37 (+120.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +8.16%2025-09-11 → 2026-09-11$78.01 → $84.37 (+8.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+4.06%2023-09-11 → 2026-09-11$74.87 → $84.37 (+12.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-6.94%2021-09-10 → 2026-09-11$120.89 → $84.37 (-30.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+8.24%2016-09-09 → 2026-09-11$38.20 → $84.37 (+120.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 48.8×2016-09 46.722026-09 48.42+3.6% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 33.6×2017-03 26.272026-09 33.58+27.8% over the window
Fwd P/E: 26.6×
P/S (ttm)Market cap ÷ TTM revenue.: 7.5×2016-09 8.992026-09 7.47-16.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.6×2016-09 9.582026-09 4.58-52.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 33.9×2016-09 56.442026-09 33.94-39.9% over the window
EV/EBITDA (fy): 28.0×
EV/Sales (ttm): 6.9×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.95%2016-06 1.8%2026-06 2.8%+49.6% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 576.4M ÷ 587.1M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 1.82%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (1.82%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($45.9B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 1.82%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($1.2B) ÷ today's market cap ($48.6B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.48%2016-06 1.9%2026-06 2.3%+24.2% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $1.2B + TTM dividends $0) ÷ today's market cap ($48.6B). Same caveat as the cash buyback yield.: 2.48%2016-06 1.9%2026-06 2.3%+24.2% over the window

Vs own 10Y history

P/E: 72nd
P/OI: 41st
P/S: 13th
P/B: 12th
P/FCF: 3rd

Bar = where today’s multiple sits in EW’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

-2.77%

-6.03%

-9.33%

-1.62%

YTD

-1.03%

+7.78%

-30.05%

Financial statements

Open full EW financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

Edwards Lifesciences Corporation (EW) trades at $84.37 with a live price and an interactive chart covering 26+ years of daily price history, plus key valuation metrics. ChartRow also publishes EW’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full EW financial statements →

EW — Edwards Lifesciences Corporation price, chart and key statistics